To better understand the association between PTEN deficiency and response to TKIs, we assessed PTEN expression in all of the 19 endometrial cancer cell lines using western blot analysis and compared the in vitro sensitivity towards lapatinib between lines with low and those with high expression levels (Figure 2B). This evidence concerns the gene PTEN and endometrial cancer.